Macitentan

Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH). The other two ERAs marketed as of 2014 are bosentan and ambrisentan. Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET_A and ET_B. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype. The drug received approval from the U.S. Food and Drug Administration (FDA) on October 13, 2013.

单词	Macitentan
释义	Macitentan 英语百科 Macitentan Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH). The other two ERAs marketed as of 2014 are bosentan and ambrisentan. Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET_A and ET_B. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype. The drug received approval from the U.S. Food and Drug Administration (FDA) on October 13, 2013.
随便看	resonance energyRE resonance energy region Resonance energy transfer Resonance enhanced multiphoton ionization resonance envelope resonance epithermal reactor resonance error resonance escape resonance escape factor resonance escape probability resonance excitation resonance excitation of betatron oscillations resonance feature resonance, ferromagnetic investigation of materials resonance field resonance filter resonance fission resonance fission integral Resonance fluorescence resonance fluorescence lidar resonance fluorescence technique resonance flux resonance formula resonance, frequency Resonance frequency